P2X7 receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2611-2619

  Lopez Castejon, Gloria ^a   Theaker, Jill ^b   Pelegrin, Pablo ^a,c   Clifton, Andrew D ^b   Braddock, Martin ^b   Surprenant, Annmarie ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ADENOSINE TRIPHOSPHATE; AZ 10573295; AZ 10603690; AZ 11648720; CATHEPSIN B; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CYSTEINE PROTEINASE; DICLOFENAC; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; MAB 206; METHOTREXATE; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPTIDE HYDROLASE INHIBITOR; PREDNISOLONE; PURINERGIC P2X7 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; AZ 11645373; CATHEPSIN; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PURINERGIC P2 RECEPTOR; THIAZOLE DERIVATIVE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; CELL DEATH; CYTOKINE PRODUCTION; DEGRADATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE INJURY; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; L CELL; METABOLISM; MOUSE MUTANT; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CATHEPSIN B; CATHEPSINS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; JOINT DISEASES; L CELLS (CELL LINE); MACROPHAGES; METHOTREXATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR STRUCTURE; RECEPTORS, PURINERGIC P2; RECEPTORS, TUMOR NECROSIS FACTOR; THIAZOLES;

EID: 77956936562     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000436     Document Type: Article

References (62)

1. Bianchi, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81: 1-5.
2. Willart, M. A., and B. N. Lambrecht. 2009. The danger within: endogenous danger signals, atopy and asthma. Clin. Exp. Allergy 39: 12-19.
3. Pétrilli, V., C. Dostert, D. A. Muruve, and J. Tschopp. 2007. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19: 615-622.
4. Franchi, L., T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez. 2009. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10: 241-247.
5. 7) and the inflammasome. Trends Pharmacol. Sci. 28: 465-472.
6. 7 receptor: a key player in IL-1 processing and release. J. Immunol. 176: 3877-3883.
7. 7 receptor. Neuropharmacology 36: 1277-1283.
8. Surprenant, A., and R. A. North. 2009. Signaling at purinergic P2X receptors. Annu. Rev. Physiol. 71: 333-359.
9. North, R. A. 2002. Molecular physiology of P2X receptors. Physiol. Rev. 82: 1013-1067.
10. 7) receptor antagonists for chronic inflammation and pain. Purinergic Signal. 5: 63-73.
11. Guile S.D., L. Alcaraz, T.N. Birkinshaw, K.C. Bowers, M.R. Ebden, M. Furber, M.J. Stocks. 2009. Antagonists of the P2X7 receptor. From lead identification to drug development. J. Med. Chem. 52: 3123-3141.
12. 7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 179: 1913-1925.
13. 7 receptor in the release of IL-1 beta in the murine brain. Brain Behav. Immun. 22: 234-244.
14. Gu, B., L. J. Bendall, and J. S. Wiley. 1998. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92: 946-951.
15. 7 receptors support rapid prothrombotic responses. Cell. Signal. 19: 855-866.
16. 7 receptor. Blood 107: 4946-4953.
17. Andrei, C., C. Dazzi, L. Lotti, M. R. Torrisi, G. Chimini, and A. Rubartelli. 1999. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell 10: 1463-1475.
18. Vasiljeva, O., T. Reinheckel, C. Peters, D. Turk, V. Turk, and B. Turk. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13: 387-403.
19. Wang, D., and D. Brömme. 2005. Drug delivery strategies for cathepsin inhibitors in joint diseases. Expert Opin. Drug Deliv. 2: 1015-1028.
20. Yan, S., and B. F. Sloane. 2003. Molecular regulation of human cathepsin B: implication in pathologies. Biol. Chem. 384: 845-854.
21. Zavasnik-Bergant, T., and B. Turk. 2006. Cysteine cathepsins in the immune response. Tissue Antigens 67: 349-355.
22. Geborek, P., T. Saxne, H. Pettersson, and F. A. Wollheim. 1989. Synovial fluid acidosis correlates with radiological joint destruction in rheumatoid arthritis knee joints. J. Rheumatol. 16: 468-472.
23. Lardner, A. 2001. The effects of extracellular pH on immune function. J. Leukoc. Biol. 69: 522-530.
24. Hashimoto, Y., H. Kakegawa, Y. Narita, Y. Hachiya, T. Hayakawa, J. Kos, V. Turk, and N. Katunuma. 2001. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun. 283: 334-339.
25. Nakagawa, T. Y., W. H. Brissette, P. D. Lira, R. J. Griffiths, N. Petrushova, J. Stock, J. D. McNeish, S. E. Eastman, E. D. Howard, S. R. Clarke, et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10: 207-217.
26. Saftig, P., E. Hunziker, V. Everts, S. Jones, A. Boyde, O. Wehmeyer, A. Suter, and K. von Figura. 2000. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv. Exp. Med. Biol. 477: 293-303.
27. Handel-Fernandez, M. E., and D. M. Lopez. 2000. Isolation of macrophages from tissues, fluids, and immune response sites. In Macrophages, 1st Ed. D. M. Paulnock, ed. Oxford University Press, New York, p. 1-30.
28. MacKenzie, A., H. L. Wilson, E. Kiss-Toth, S. K. Dower, R. A. North, and A. Surprenant. 2001. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15: 825-835.
29. 7 receptor. J. Immunol. 175: 7623-7634.
30. Giusti, I., S. D'Ascenzo, D. Millimaggi, G. Taraboletti, G. Carta, N. Franceschini, A. Pavan, and V. Dolo. 2008. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 10: 481-488.
31. 7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J. Leukoc. Biol. 64: 265-273.
32. von Kügelgen, I. 2006. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol. Ther. 110: 415-432.
33. Tulone, C., J. Tsang, Z. Prokopowicz, N. Grosvenor, and B. Chain. 2007. Natural cathepsin E deficiency in the immune system of C57BL/6J mice. Immunogenetics 59: 927-935.
34. Kirschke, H. 1981. On the substrate specificity of cathepsin L. Acta Biol. Med. Ger. 40: 1427-1431.
35. Khouri, H. E., C. Plouffe, S. Hasnain, T. Hirama, A. C. Storer, and R. Ménard. 1991. A model to explain the pH-dependent specificity of cathepsin B-catalysed hydrolyses. Biochem. J. 275: 751-757.
36. Claveau, D., D. Riendeau, and J. A. Mancini. 2000. Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells. Biochem. Pharmacol. 60: 759-769.
37. Stroup, G. B., M. W. Lark, D. F. Veber, A. Bhattacharyya, S. Blake, L. C. Dare, K. F. Erhard, S. J. Hoffman, I. E. James, R. W. Marquis, et al. 2001. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16: 1739-1746.
38. Katunuma, N., Y. Matsunaga, K. Himeno, and Y. Hayashi. 2003. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol. Chem. 384: 883-890.
39. Perregaux, D., and C. A. Gabel. 1994. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269: 15195-15203.
40. Dubyak, G. R. 2000. Purinergic signaling at immunological synapses. J. Auton. Nerv. Syst. 81: 64-68.
41. Di Virgilio, F., P. Chiozzi, D. Ferrari, S. Falzoni, J. M. Sanz, A. Morelli, M. Torboli, G. Bolognesi, and O. R. Baricordi. 2001. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97: 587-600.
42. Brunk, U. T., J. Neuzil, and J. W. Eaton. 2001. Lysosomal involvement in apoptosis. Redox Rep. 6: 91-97.
43. Pelegrin, P., and A. Surprenant. 2009. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 28: 2114-2127.
44. North, R. A., and A. Surprenant. 2000. Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 40: 563-580.
45. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 13: 4047-4050.
46. 7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. Am. J. Physiol. Cell Physiol. 285: C286-C299.
47. + release. Am. J. Physiol. Cell Physiol. 286: C1100-C1108.
48. Andrews, N. W. 2000. Regulated secretion of conventional lysosomes. Trends Cell Biol. 10: 316-321.
49. Sundler, R. 1997. Lysosomal and cytosolic pH as regulators of exocytosis in mouse macrophages. Acta Physiol. Scand. 161: 553-556.
50. 7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J. Cell Sci. 112: 297-305.
51. Sumiya, S., T.Yoneda,K.Kitamura, M.Murata, C.Yokoo,M. Tamai,A.Yamamoto, M. Inoue, and T. Ishida. 1992. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction. Chem. Pharm. Bull. (Tokyo) 40: 299-303.
52. 7) receptor antagonists/interleukin-1beta inhibitors. J. Med. Chem. 50: 5882-5885.
53. Bingham, C. O., III. 2008. Emerging therapeutics for rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 66: 210-215.
54. Banning, M. 2006. The use of topical diclofenac for pain in osteoarthritis of the knee: a review. Br. J. Community Nurs. 11: 487-492.
55. Gotzsche, P. C., and H. K. Johansen. 2004. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst. Rev. (3):):CD000189.
56. Kremer, J. M. 2001. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med. 134: 695-706.
57. Turk, B., V. Turk, and D. Turk. 1997. Structural and functional aspects of papainlike cysteine proteinases and their protein inhibitors. Biol. Chem. 378: 141-150.
58. Pungercar, J. R., D. Caglic, M. Sajid, M. Dolinar, O. Vasiljeva, U. Pozgan, D. Turk, M. Bogyo, V. Turk, and B. Turk. 2009. Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J. 276: 660-668.
59. Brough, D., and N. J. Rothwell. 2007. Caspase-1-dependent processing of prointerleukin-1beta is cytosolic and precedes cell death. J. Cell Sci. 120: 772-781.
60. Boya, P., and G. Kroemer. 2008. Lysosomal membrane permeabilization in cell death. Oncogene 27: 6434-6451.
61. Baici, A., D. Hörler, A. Lang, C. Merlin, and R. Kissling. 1995. Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann. Rheum. Dis. 54: 281-288.
62. Baici, A., A. Lang, D. Horler, R. Kissling, and C. Merlin. 1995. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann. Rheum. Dis. 54: 289-297.